Bruker Corporation

BRKR Healthcare Medical Devices

Bruker Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.4 billion, up 2.08% from fiscal 2024. In the quarter to June 2026, revenue grew 5.15%, EPS fell 920.0%, free cash flow grew 28.6% and total debt fell 25.1%, each against the same quarter a year earlier. Dividend growth for ten consecutive years, revenue growth for five.

54.80 1.74 −3.08%
Market cap
$8.6B
P/E
0.0×
Fwd P/E
55.7×
Dividend yield
0.36%
F-score
4/9
Altman Z
2.43
Beneish M
−2.56
Dividend safety
34/100
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
0.00 0.00 0.00 0.00

+8 more quarters

P/S ratio
2.62 1.59 2.08 1.43
P/FCF ratio
77.21 72.24 105.01 347.32
P/Operating CF
(118.42) 77.21 31.12 (148.55)
P/B ratio
3.82 2.23 2.89 2.01
EV/Sales
3.09 2.03 2.54 1.93
EV/EBITDA
54.16 25.60 30.23 23.82
EV/FCF
91.03 92.45 128.07 468.13
Current Ratio
1.85 1.55 1.73 1.85
Net Debt/EBITDA
(224.64) 22.45 11.68 439.85
Debt/Equity
0.76 0.68 0.76 0.82
Earnings Yield
(1.16%) (0.66%) (0.32%) (0.49%)
Free Cash Flow Yield
1.30% 1.38% 0.95% 0.29%
Free Cash Flow per Share
(0.70) 0.31 1.37 (0.36)
Book value per Share
15.76 16.21 16.29 16.14
Free Cash Flow
(106.20) 47.00 207.20 (54.10)
EV/EBIT
0.00 150.97 127.88 103.87
Other line items

Show all line items

Columns are period end dates